Post-earnings recap
Reported
Tue, Nov 7, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a loss per share of $0.28, but no revenue figures were disclosed. The stock reacted negatively, declining by 1.7%. The lack of guidance and commentary from management may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.